JP2021505137A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505137A5 JP2021505137A5 JP2020530356A JP2020530356A JP2021505137A5 JP 2021505137 A5 JP2021505137 A5 JP 2021505137A5 JP 2020530356 A JP2020530356 A JP 2020530356A JP 2020530356 A JP2020530356 A JP 2020530356A JP 2021505137 A5 JP2021505137 A5 JP 2021505137A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence number
- amino acid
- chain variable
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108010005327 CD19-specific chimeric antigen receptor Proteins 0.000 claims description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 54
- 125000003275 alpha amino acid group Chemical group 0.000 claims 36
- 239000012636 effector Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 18
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 5
- 101100273212 Arabidopsis thaliana CAR7 gene Proteins 0.000 description 3
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 101100005008 Mus musculus Ca7 gene Proteins 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- -1 CD8 (CD8α) Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 102100024633 Carbonic anhydrase 2 Human genes 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000760643 Homo sapiens Carbonic anhydrase 2 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000013602 bacteriophage vector Substances 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170166969 | 2017-12-06 | ||
| KR10-2017-0166969 | 2017-12-06 | ||
| PCT/KR2018/015445 WO2019112347A2 (ko) | 2017-12-06 | 2018-12-06 | 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505137A JP2021505137A (ja) | 2021-02-18 |
| JP2021505137A5 true JP2021505137A5 (enExample) | 2021-12-02 |
| JP7089806B2 JP7089806B2 (ja) | 2022-06-23 |
Family
ID=66749962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530356A Active JP7089806B2 (ja) | 2017-12-06 | 2018-12-06 | 悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11534462B2 (enExample) |
| EP (1) | EP3722313A4 (enExample) |
| JP (1) | JP7089806B2 (enExample) |
| KR (1) | KR102136063B1 (enExample) |
| CN (1) | CN111465616B (enExample) |
| AU (1) | AU2018379502B2 (enExample) |
| CA (1) | CA3083936C (enExample) |
| WO (1) | WO2019112347A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210079111A1 (en) * | 2018-08-04 | 2021-03-18 | AbCyte Therapeutics Inc. | Cd19-cd20 bispecific and dual passway car-t and methods for use thereof |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CN112759651B (zh) * | 2019-11-01 | 2022-09-20 | 北京华夏清医治疗科技有限公司 | 一种包含嵌合抗原受体修饰的t细胞及其应用 |
| CN111909277A (zh) * | 2020-08-13 | 2020-11-10 | 上海市第一人民医院 | 一种靶向trbc1的人源化嵌合抗原受体、t细胞及用途 |
| KR102393776B1 (ko) * | 2020-12-30 | 2022-05-04 | (주)이노베이션바이오 | Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체 |
| WO2022234158A1 (es) * | 2021-05-06 | 2022-11-10 | Institut D'investigacions Biomèdiques August Pi I Sunyer (Idibaps) | Terapia de células t con receptor de antígeno quimérico específico de cd19 |
| US20230399375A1 (en) | 2022-04-15 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
| US20240261405A1 (en) | 2022-06-08 | 2024-08-08 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
| CN118359729A (zh) * | 2023-01-19 | 2024-07-19 | 武汉昭智生物技术有限公司 | 一种car分子、包含其的细胞或外泌体及它们的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US7169894B2 (en) * | 2001-11-14 | 2007-01-30 | Mirari Biosciences, Inc. | Methods and compositions for reverse translation |
| US20060280738A1 (en) | 2005-06-08 | 2006-12-14 | Tedder Thomas F | Anti-CD19 antibody therapy for transplantation |
| KR101289537B1 (ko) * | 2005-02-15 | 2013-07-31 | 듀크 유니버시티 | 항-ｃｄ19 항체 및 종양학에서 이의 용도 |
| KR20080032097A (ko) * | 2005-06-20 | 2008-04-14 | 메다렉스, 인코포레이티드 | 씨디19 항체 및 그의 용도 |
| EP3482769B1 (en) * | 2008-12-19 | 2024-05-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| EP2398829A2 (en) * | 2009-02-23 | 2011-12-28 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| CA2754266A1 (en) * | 2009-03-06 | 2010-09-10 | Medimmune, Llc | Humanized anti-cd19 antibody formulations |
| US9074002B2 (en) * | 2009-04-27 | 2015-07-07 | Cold Spring Harbor Laboratory | PTP1B inhibitors |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| BR112015028387B1 (pt) | 2013-05-13 | 2023-04-11 | Cellectis | Receptor antigênico quimérico específico para cd19, polinucleotídeo, vetor de expressão, método in vitro para manipulação e uso de uma célula imune |
| SG11201509609SA (en) | 2013-05-24 | 2015-12-30 | Univ Texas | Chimeric antigen receptor-targeting monoclonal antibodies |
| GB2527285B (en) | 2014-06-11 | 2021-05-26 | Advanced Risc Mach Ltd | Resource access control using a validation token |
| TWI805109B (zh) * | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| CN109824778B (zh) | 2015-09-18 | 2022-07-19 | 上海科济制药有限公司 | 抗cd19全人抗体以及靶向cd19的免疫效应细胞 |
| SG11201803054UA (en) * | 2015-10-13 | 2018-05-30 | Eureka Therapeutics Inc | Antibody agents specific for human cd19 and uses thereof |
-
2018
- 2018-12-06 US US16/768,412 patent/US11534462B2/en active Active
- 2018-12-06 EP EP18886531.5A patent/EP3722313A4/en active Pending
- 2018-12-06 AU AU2018379502A patent/AU2018379502B2/en active Active
- 2018-12-06 CN CN201880079137.7A patent/CN111465616B/zh active Active
- 2018-12-06 KR KR1020180156433A patent/KR102136063B1/ko active Active
- 2018-12-06 CA CA3083936A patent/CA3083936C/en active Active
- 2018-12-06 JP JP2020530356A patent/JP7089806B2/ja active Active
- 2018-12-06 WO PCT/KR2018/015445 patent/WO2019112347A2/ko not_active Ceased
-
2022
- 2022-12-06 US US18/075,648 patent/US12090171B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505137A5 (enExample) | ||
| JP7404335B2 (ja) | Ｂｃｍａ特異性を有するキメラ抗原受容体およびその使用 | |
| CN109485734B (zh) | 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用 | |
| CA3032581A1 (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| JP7721500B2 (ja) | Ｍａｇｅ－ａ４特異性を有するキメラ抗原受容体およびそれらの使用 | |
| KR20180054590A (ko) | 항글리피칸-3 항체 및 이의 응용 | |
| JP2018526028A5 (enExample) | ||
| US20240123068A1 (en) | Cd19 binders, car-t constructs comprising the same, and methods of using the same | |
| WO2018071913A2 (en) | Modular tetrameric bispecific antibody platform | |
| CN111848809A (zh) | 靶向Claudin18.2的CAR分子、其修饰的免疫细胞及用途 | |
| CN108883181A (zh) | 在免疫疗法中抑制TGFβ | |
| TW202246504A (zh) | 靶向嵌合抗原受體之ｒｏｒ１ | |
| KR20230022422A (ko) | 항-her2 어피바디 및 이를 스위치 분자로 이용하는 스위처블 키메라 항원 수용체 | |
| KR20240013173A (ko) | Nkg2d-기초 키메라 항원 수용체 | |
| US20240226154A9 (en) | Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same | |
| JP7080514B2 (ja) | 悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途 | |
| TW202309294A (zh) | 病毒載體生產系統 | |
| JPWO2021016585A5 (enExample) | ||
| KR20240052776A (ko) | Mog-결합 단백질 및 이의 용도 | |
| JPWO2022235662A5 (enExample) | ||
| US20250041419A1 (en) | Modified Cytotoxic T Cells and Methods of Use Thereof | |
| AU2023230479A1 (en) | Antibody or antigen-binding fragment thereof that targets cotinine, chimeric antigen receptor comprising same, and uses thereof | |
| TW202435913A (zh) | 針對血癌之抗體 | |
| CN117412985A (zh) | 靶向ror1的嵌合抗原受体 | |
| HK40072388A (en) | TGF-β RECEPTORS AND METHODS OF USE |